65,437 trials
Cirrhosis · Chronic Hepatitis C · Hepatitis C
Primary: Changes in Interferon Stimulated Genes in the Liver — -0.04915; -0.35948; -0.49980; -0.79328 relative expression
Melanoma
Primary: Overall Response Rate (ORR) — 10 Percentage of Participants
Thyroid Cancer
Primary: Progression Free Survival (PFS) — 18.3; 3.6 months
Tetraplegia · Spinal Cord Injury · Brachial Plexus Injury
Primary: Number of Participants Able to Successfully Control of a Variety of External Devices Using Neural Data Recorded With ECoG — 3 participants
Pulmonary Tuberculosis
Primary: The Rate of Change in Colony Forming Units (CFUs) Using Non-linear Mixed Effects Modeling of the Serial Sputum Colony Counts (SSCC) Over 8 Weeks of Treatment. — 0.133…
Non-small Cell Lung Cancer
Primary: 6-month Progression Free Survival Rate — 74 percentage of participants
Substance Use · Psychopathy
Primary: Percent Days Abstinent Per Month From Drug Use — 46.92; 55.16 percentage of days abstinent — p=.02
Pancreatic Cancer · Venous Thromboembolism
Primary: Number of Participants With Venous Thromboembolic Events (VTE) — 2; 9 participants
Other Obstetric Trauma - Delivered
Primary: Partecipant With Perineal Laceration — 3; 31 participants
Diabetes Mellitus, Type 2
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — -0.19; -0.73; -0.85 percentage of hemoglobin — p=<0.0001
Lymphocytic Leukemia
Primary: Clinical Response (Complete or Partial Remission) — 0; 1; 0; 3 participants
Myelodysplastic Syndrome
Primary: Adverse Events — 1 participants
Cocaine Abuse · Cocaine Dependence
Primary: Mean Number of Days Per Week of Cocaine Use — 0.41; 1.15; 0.43; 1.01 number of days per week of cocaine use — p=0.010
Hypertension · Blood Pressure
Primary: Percentage of Subjects Doing Home BP Monitoring — 54; 46; 68; 64 percentage of subjects doing HBPM — p=0.27
Influenza
Primary: Number of Participants With Solicited Injection-Site or Systemic Reactions After Receipt of the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal…